We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Our information suggests that insiders maintain a significant holding in Microvast Holdings, Inc.. It has a market capitalization of just US$638m, and insiders have US$188m worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.
Free Barchart Webinar
GAIN Capital Holdings, Inc is based in Bedminster, New Jersey. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.
We can see that Microvast Holdings does have institutional investors; and they hold a good portion of the company’s stock. This suggests some credibility amongst professional investors. But we can’t rely on that fact alone since institutions make bad investments sometimes, just like everyone does.
Advanced Stock Screeners and Research Tools
Trailing the large companies in the Exchange Traded Funds Etf sector, some overlooked companies are coming in with their earnings. BCHG revealed it has realized operating shortfall of $-1.027 million, for the second quarter of 2025. Part of StoneX Group, Inc., GAIN Capital Group LLC operates an online forex trading platform. Upgrade to MarketBeat All Access to add more stocks to your watchlist.
Financial Calendars
However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it’s included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
GCAP Related stocks
In addition to progressing GT through the clinic, we will look to add to its extensive preclinical data package with further presentations at scientific conferences and hope to inform the industry and academia of our successful progress. Please bear with us as we address this and restore your personalized lists. All market data (will open in new tab) is provided by Barchart Solutions. The general public, who are usually individual investors, hold a 44% stake in Microvast Holdings.
- Results from a Phase 1 study of GT in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme.
- Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
- While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing.
- In early December 2024, we held a productive pre-IND meeting with the FDA and received encouraging feedback that aligned with our expectations.
- In December 2024, we received approval to initiate our Phase 1b clinical trial of GT in people with GBA1 or idiopathic Parkinson’s disease.
- The definition of company insiders can be subjective and does vary between jurisdictions.
Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggests that GT may have the potential to slow or stop the progression of Parkinson’s disease. Parkinson’s disease remains the second most common neurodegenerative disease after Alzheimer’s and yet there are only symptomatic treatments available to patients. We hope 2025 is a year of immense progress – not only for Gain but the field lexatrade review as a whole – and look forward to GT taking one step closer to potentially being the first disease-modifying therapy for Parkinson’s disease.
Information is provided ‘as is’ and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab). Part of StoneX Group, Inc., StoneX Financial Pty Ltd. is an Australian company that distributes electronic goods related to stock trading. Sean Michael O’Connor has been the CEO of the company since 2002. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.
Top Third Unveils New StoneX Brand & Services
Our clinical team led by Gain’s Chief Medical Officer, Jonas Hannestad, is currently working closely with seven clinical centers in Australia to begin dosing the first patients in the Phase 1b clinical trial, which we expect to happen imminently. We expect to provide an enrollment update by the end of 1Q 2025 and guidance in 2Q 2025 when we expect to be in position to discuss interim analysis of the Phase 1b clinical trial. Private equity firms hold a 13% stake in Microvast Holdings. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the https://www.forex-world.net/ investment after taking it public.
- As a reminder, we are planning on enrolling individuals with either GBA1 or idiopathic Parkinson’s disease – all of whom will receive oral GT daily for three months in the open-label Phase 1b clinical trial.
- We hope 2025 is a year of immense progress – not only for Gain but the field as a whole – and look forward to GT taking one step closer to potentially being the first disease-modifying therapy for Parkinson’s disease.
- Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
- We aim to bring you long-term focused analysis driven by fundamental data.
- Part of StoneX Group, Inc., StoneX Financial Pty Ltd. is an Australian company that distributes electronic goods related to stock trading.
Enter your email address and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Provides a general description of the business conducted by this company.
About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme. We believe that our Phase 1b clinical trial will illustrate that the broad neuroprotective effect demonstrated in pre-clinical models of Parkinson’s disease will translate to human participants with Parkinson’s disease. We believe this may unlock significant value for the GT development program through 2025 and beyond. The fight against Parkinson’s disease is one we at Gain are truly committed to.
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders Hedging forex to balance the interests of the larger ones to a certain extent. Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Explore comprehensive options data and use advanced filters with Options Flow.